P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS

Authors: P. Abraham, X. Liao, M. Chevli, S. Smith

Published: 2022-06-23

DOI: 10.1097/01.hs9.0000847112.18637.3d

Source: Full article

---

Abstract

No abstract found.